calicheamicin


Also found in: Wikipedia.

calicheamicin

Any of a family of antitumour antibiotics derived from Micromonospora calichensis and Actinomadura verrucosospora, which have 4000-fold greater antitumoural activity than adriamycin, share a motif of double-triple-double carbon bonds (a so-called enediyene) and cleave DNA in a double-stranded fashion at specific DNA sequences.
Mentioned in ?
References in periodicals archive ?
Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin.
According to the study, calicheamicin, a secondary metabolite of Micromonospora echinospora, is what gave the river its toxic reputation.
Mylotarg, a combination of gemtuzumab (IgG4k) conjugated with the cytotoxic antitumor antibiotic calicheamicin, is indicated for the treatment of patients with CD33-positive acute myeloid leukemia in first relapse who are 60 years of age or older.
Nicolaou is world-renowned for the total synthesis of calicheamicin, Taxol(TM), vancomycin, and many other naturally occurring molecules
Whitwam (Mississippi University for Women) who presented work he performed at the Sloan-Kettering Cancer Center on "Cloning and Characterizing the Calicheamicin Self-resi stance gene in Micromonospora echinospora.
Antibody-Targeted Chemotherapy with CMC-544: a CD22-Targeted Immunoconjugate of Calicheamicin for the Treatment of B-Lymphoid Malignancies.
CLONING AND CHARACTERIZING THE CALICHEAMICIN SELF-RESISTANCE GENE IN MICROMONOSPORA ECHINOSPORA
The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.
Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma.
Ellestad's group to unravel the bioreductive activation and DNA cleavage chemistry of calicheamicin which helped pave the way for the development of the first antibody-targeted chemotherapy.
Under an agreement with Wyeth, Celltech Group humanized the anti-CD33 antibody and co-developed the chemical linker between the antibody and calicheamicin.
CMC-544 CMC-544 is an anti-CD22 antibody linked to calicheamicin, a potent cytoxic drug, using technology developed for the FDA-approved drug Mylotarg.